Back to MAPS Medical Marijuana Page
Cannabis in Migraine Treatment Study
February 2000. While Dr. Russo is seeking to study cannabis in the treatment of migraines, he has discussed patient reports and biological studies that suggest a variety of psychedelics could also be helpful to patients with migraines and cluster headaches.
-----Original Message----- Dear Dr. Russo,
I have been reading about your research on the web. Have any of your
studies taken you into the field of Cluster Headaches? I ask because our message board at
www.clusterheadaches.com has recently seen quite
a few posts about using liberty cap mushrooms to treat Clusters. This is
one of the most recent:
clusterheadaches.com/wwwboard/messages/40125.html
We are having a convention in August. The info is at the site. It may or
may not interest you.
Thanks Dear Dennis,
We are in a touchy area here, inasmuch as Psilocybe mushrooms are illegal
in most countries. Their potencies vary. An untrained person can not know
absolutely whether a given mushroom is the species they desire, let alone
its potency. It might be a fine line between a dose that alleviates
headache, and one that produces a blowout 4 hour psychedelic trip.
Obviously, I can not specifically recommend this treatment as something that
you or anyone else should try. Peroutka, S.J., "Developments in 5-hydroxytryptamine Receptor Pharmacology in Migraine", in Mathew, N. (Ed.), Headache, Neurologic Clinics of North America 8:829-839, 1990.
It says that to treat migraine (and cluster) acutely, one desires a drug or
plant that will stimulate serotonin type 1 (1A or 1D) receptors. To treat
headaches preventively, one desires a drug or plant that will inhibit
serotonin type 2A receptors (see 3rd URL). It may turn out that there are
additional effects on NMDA receptors, but this will suffice for now.
Interestingly, these serotonin effects may be one of the key mechanisms of
hallucinogenesis. All the examples I gave above fit this profile. The
problem develops then, that we have available a very fertile area of
research that could alleviate the suffering of many migraine and cluster
patients. However, many such agents are Schedule I drugs, meaning that the
DEA and US Government consider them prohibitively dangerous, and possessing
no recognized medical usage. The law is blind and biased. As a result, I
have had shoestring funding of my theories, and have been unable after 3
years of effort to begin a clinical trial of cannabis in migraine treatment
(1st URL).
Best wishes,
Read more about MAPS' support of medical marijuana research
|